Chemours (CC) Expected to Release Quarterly Earnings on Monday

Chemours (NYSE:CC) is projected to post its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to announce earnings of $0.2662 per share and revenue of $1.53 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 8:00 AM ET.

Chemours (NYSE:CC) last posted its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.65 billion. Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter last year, the business posted ($2.54) earnings per share. On average, analysts expect Chemours to post $0.83 EPS for the current fiscal year and $1.92 EPS for the next fiscal year.

Chemours Stock Up 0.0%

NYSE:CC opened at $12.82 on Monday. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -6.71 and a beta of 1.41. Chemours has a one year low of $10.44 and a one year high of $28.67. The stock has a 50-day simple moving average of $14.46 and a 200 day simple moving average of $18.54.

Chemours Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th were paid a dividend of $0.0875 per share. The ex-dividend date was Friday, August 14th. This represents a $0.35 annualized dividend and a yield of 2.7%. Chemours’s dividend payout ratio is presently -18.32%.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Negative Sentiment: Several law firms announced or promoted the same federal securities class action against Chemours and certain executives. The complaint covers investors who purchased CC securities from February 20 through August 4, 2026, and alleges that the company made material misstatements or omissions concerning the reliability of its financial guidance. The allegations have not been proven. Kessler Topaz securities-fraud lawsuit announcement
• Negative Sentiment: The complaint reportedly focuses on Chemours’ 2026 outlook and alleged failure to disclose that an oversupplied Opteon aftermarket channel was weakening demand. If sustained, the claims could create litigation costs, reputational risk and additional scrutiny of the company’s disclosures. SueWallSt Chemours class-action deadline alert
• Neutral Sentiment: Investors have until December 7, 2026, to apply to become lead plaintiff; the deadline is procedural and does not determine the lawsuit’s outcome or establish liability. Multiple alerts from ClaimsFiler, Pomerantz, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Glancy Prongay and Frank R. Cruz largely repeat this information. Frank R. Cruz deadline alert

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Mizuho reaffirmed a “neutral” rating and set a $15.00 target price (down from $18.00) on shares of Chemours in a report on Wednesday, October 14th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $16.00 price target on shares of Chemours in a report on Friday, October 9th. Barclays started coverage on Chemours in a report on Monday, October 12th. They issued an “equal weight” rating and a $16.00 price target for the company. UBS Group dropped their price target on Chemours from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Monday, October 5th. Finally, JPMorgan Chase & Co. reduced their price objective on Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 13th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $17.73.

Insider Activity

In other Chemours news, CEO Denise Dignam acquired 3,378 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was acquired at an average price of $14.95 per share, with a total value of $50,501.10. Following the transaction, the chief executive officer directly owned 339,916 shares in the company, valued at approximately $5,081,744.20. This represents a 1.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average cost of $15.53 per share, with a total value of $30,050.55. Following the transaction, the insider owned 58,547 shares in the company, valued at approximately $909,234.91. The trade was a 3.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 8,663 shares of company stock valued at $130,601. Company insiders own 0.85% of the company’s stock.

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.